Expression of miR-221 and miR-489 in breast cancer patients and their relationship with prognosis.

Expression of miR-221 and miR-489 in breast cancer patients and their relationship with prognosis. Oncol Lett. 2020 Feb;19(2):1523-1529 Authors: Li F Abstract Expression of miR-221 and miR-489 in breast cancer patients and their prognostic value were investigated. Sixty-two breast cancer patients admitted to the First Teaching Hospital of Tianjin University of Traditional Chinese Medicine for tumor surgery, from July 2014 to January 2016, were selected as the research group (RG), and 27 female adults who underwent physical examination during the same period were selected as the control group (CG). miR-221 and miR-489 expression levels in the blood samples of the breast cancer patients and the healthy female adults were detected by fluorescence reverse transcription-quantitative PCR (RT-qPCR), and the relationship of the expression levels of miR-221 and miR-489 with the disease prognosis was analyzed. The expression levels of miR-221 and miR-489 in the blood samples of breast cancer patients were 7.13±1.19 and 0.88±0.09, respectively, and those in the blood samples of healthy individuals were 5.82±0.84 and 1.01±0.12, respectively. The expression level of miR-221 in the RG was significantly higher than that in the CG (P
Source: Oncology Letters - Category: Cancer & Oncology Tags: Oncol Lett Source Type: research

Related Links:

Publication date: Available online 19 February 2020Source: Molecular and Cellular EndocrinologyAuthor(s): Tenghua Yu, Hong Cheng, Zhijuan Ding, Zhiliang Wang, Lixia Zhou, Peng Zhao, Shengxing Tan, Xue Xu, Xianming Huang, Manran Liu, Meixi Peng, Yu-an QiuAbstractRescue chemotherapy is usually the preferred treatment for patients with advanced estrogen receptor-positive (ER+) breast cancer with endocrinotherapy resistance. However, these patients often simultaneously show a poor response to cytotoxic drugs, and thus the detailed mechanism of this resistance needs to be further investigated. Our previous research indicated th...
Source: Molecular and Cellular Endocrinology - Category: Endocrinology Source Type: research
Conclusion GRPR and integrin αvβ3 expression results are complementary to 18F-FDG PET/CT findings, and are also significantly correlated with hormone receptors associated with aggressive subtypes. These results may pave the way for GRPR and integrin αvβ3 targeted imaging with 68Ga-labeled molecules and systemic radionuclide treatment with 177Lu-labeled compounds.
Source: Nuclear Medicine Communications - Category: Nuclear Medicine Tags: Original Articles Source Type: research
Conclusion EORTC criteria and PERCIST had early predictive value to long-term outcome, but moderate value for pCR. Furthermore, PERCIST might show more potential than the EORTC criteria and conventional PET-based parameters to predict prognosis in breast cancer patients following two cycles of neoadjuvant chemotherapy. Video abstract: see
Source: Nuclear Medicine Communications - Category: Nuclear Medicine Tags: Original Articles Source Type: research
Source: The Doctors Lounge - Oncology - Category: Cancer & Oncology Tags: Cardiology, Gynecology, Oncology, News, Source Type: news
A patient with breast cancer at risk of infertility from adjuvant chemotherapy has given birth 5 years after having immature oocytes removed, matured in the laboratory, and then frozen.Medscape Medical News
Source: Medscape Hematology-Oncology Headlines - Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
This article reviews current data and ongoing research on atezolizumab for the treatment of breast cancer. Results of atezolizumab monotherapy trials in the context of other early immune checkpoint blockade trials in breast cancer are discussed as well as data from combination clinical trials with chemotherapy in both early stage and metastatic breast cancer. We focus on the safety and efficacy analyses from the phase III IMpassion trial that led to FDA and EMA approval of atezolizumab and nab-paclitaxel in patients whose tumor tested positive for PD-L1 by the Ventana SP142 companion diagnostic immunohistochemical assay.Ex...
Source: Expert Review of Anticancer Therapy - Category: Cancer & Oncology Tags: Expert Rev Anticancer Ther Source Type: research
WEDNESDAY, Feb. 19, 2020 (American Heart Association News) -- Red dresses and pink ribbons have helped millions of Americans become aware of the separate tolls heart disease and breast cancer take on women. But not everyone is aware of how the...
Source: - Daily MedNews - Category: General Medicine Source Type: news
Source: World Journal of Surgery - Category: Surgery Source Type: research
The publisher regrets that the author information was incorrect in the footnote. This has been corrected for the online version. The correct information is “Worapol Ngamcherdtrakul, PhD, is a scientist at PDX Pharmaceuticals. Dr. Ngamcherdtrakul's research is focused on developing nanoparticles for cancer-targeted co-delivery of drug and siRNA and developing topical formulations of a nanotechnology for skin diseases. He also leads the cancer immunoth erapy program at PDX Pharmaceuticals”.
Source: Translational Research - Category: Research Authors: Tags: Erratum Source Type: research
Find out how genomic testing can help steer treatment decisions in metastatic breast cancer.JCO Precision Oncology
Source: Medscape Today Headlines - Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news
More News: Breast Cancer | Cancer | Cancer & Oncology | China Health | Hospitals | Teaching | Teaching Hospitals | Universities & Medical Training